FDA Says "Not Now AVEO", HALO Axes 160 Jobs, RDHL Gets Nod For H.pylori Drug

Today's Daily Dose brings you news about AVEO Pharma's regulatory update on its investigational drug Tivozanib in renal cell carcinoma; Halozyme's decision to cut 55% workforce following phase III trial failure; FDA approval of RedHill's drug for Helicobacter pylori; revised protocol of Tonix Pharma's RECOVERY phase III study and the new Commissioner of the FDA.

from RTT - Biotech https://ift.tt/2WQ6Ye8
via IFTTT